Booth No.5H-37
CategoryOutsourcing

CURAPATH

Booth No.:5H-37
Category:Outsourcing
Company Information
Email: hosawa.e@curapath.com TEL: +34-963-76-90-80 Address: 46980
Av Benjamin Franklin 19, Paterna (Valencia), SPAIN SPAIN
URL: https://curapath.com/
Contact in Japan
Curapath is a leading CDMO specializing in innovative drug delivery systems (DDS), particularly lipid and polymer nanoparticles (LNPs and PNPs). The company offers comprehensive services, from development to IND filing, including GMP manufacturing of Drug Substance and Drug Product for clinical trials. With over a decade of experience, Curapath excels in designing and manufacturing lipid- and polymer-based delivery systems for cell therapies, gene therapies, and vaccines. The company has supported drug innovators in creating advanced excipients, polymers, and bioconjugation linkers, providing consultative guidance to ensure smooth transition from preclinical to commercial-scale manufacturing, accelerating the path to clinic.

Company information

Address 46980
Av Benjamin Franklin 19, Paterna (Valencia), SPAIN SPAIN
TEL +34-963-76-90-80
URL https://curapath.com/
Email hosawa.e@curapath.com
Product introduction Shielding Lipid
pSar (PolySarcosine)
Polyoxazoline
pSar-VitE
Cationic Lipid (Ionizable Lipid)
Lipid Synthesis
PNP (Polymeric Nano Particle)
Polymer Synthesis
Polyamino Acid
LNP (Lipid Nano Particle)
PEI (Polyethylenimine)
Fill and Finish
GMP
mRNA
PEG alternative
siRNA
CDMO
Formulation
Polypeptide
Transfection

Contact in Japan

Product introduction

Shielding LipidpSar (PolySarcosine)PolyoxazolinepSar-VitECationic Lipid (Ionizable Lipid)Lipid SynthesisPNP (Polymeric Nano Particle)Polymer SynthesisPolyamino AcidLNP (Lipid Nano Particle)PEI (Polyethylenimine)Fill and FinishGMPmRNAPEG alternativesiRNACDMOFormulationPolypeptideTransfection

New Technology Seminar

〈Free of charge〉 Same day registration

If you would like to attend, please come directly to the seminar venue.

    April 9(Wed.) 14:00 - 14:30 【6B】
    Lipid Nanoparticles & Next-Gen Excipients manufacturing: Enabling Breakthrough Therapies